Mankind Pharma stock analysis 2026 | Price, valuation & outlook

Mankind Pharma

NSEI:MANKIND

Rp 2.038,80

+ Rp14,80 (0,73%)

2.038,80 Rp

+Rp14,80 (0,73%)

End-of-day quote: 03/30/2026

Mankind Pharma Stock Value

Analysts currently rate NSEI:MANKIND as Outperform.

Outperform

Mankind Pharma Company Info

EPS Growth 5Y

11,20%

Market Cap

Rp835,57 B

Long-Term Debt

Rp55,26 B

Quarterly earnings

05/15/2026 (E)

Dividend

Rp2,04

Dividend Yield

0,10%

Founded

1991

Industry

Health Care

Country

India

Website

Mankind Pharma

ISIN Number

INE634S01028

Website

http://www.mankindpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp2.500,00

22.62%

Last Update: 03/30/2026

Analysts: 19

Highest Price Target Rp3.100,00

Average Price Target Rp2.500,00

Lowest Price Target Rp1.990,00

In the last five quarters, Mankind Pharma’s Price Target has risen from Rp2.699,07 to Rp2.766,82 - a 2,51% increase. Seventeen analysts predict that Mankind Pharma’s share price will increase in the coming year, reaching Rp2.500,00. This would represent an increase of 22,62%.

Top growth stocks in the health care sector (5Y.)

What does Mankind Pharma do?

Mankind Pharma Limited is one of India's fastest-growing pharmaceutical companies. It specializes in the development, manufacturing, and marketing of a wide range of pharmaceutical and healthcare products. Its portfolio includes prescription medications, over the counter (OTC) products, and wellness items. The company operates through a robust distribution network that spans across multiple regions, ensuring that its products are accessible to a diverse customer base. The company prides itself...

The company prides itself on innovation in drug formulation and delivery, which remains central to its business strategy. Moreover, its commitment to quality assurance and compliance with regulatory standards is paramount. The company invests significantly in research and development to discover new treatments that address various medical conditions efficiently and effectively.

The company has established a strong brand presence in the pharmaceutical market, recognized for its quality and effectiveness. The company’s emphasis on leveraging advanced technology in its manufacturing processes and maintaining high standards of quality control has helped it secure a competitive advantage. Additionally, its extensive pipeline of products in various therapeutic areas is indicative of its growth ambitions and dedication to addressing evolving healthcare needs. The company strives to contribute positively to public health through affordable medications and continues to expand its outreach in both domestic and international markets.

Business Segments

The company operates through several key business segments that underscore its diversified portfolio,

Pharmaceuticals

This segment includes the production of prescription drugs across a variety of therapeutic categories. The company invests in innovative formulations that cater to chronic and acute diseases, enabling it to meet the diverse healthcare requirements of patients. The company focuses on creating high-quality products that are both effective and safe.

Over the Counter (OTC) Products

The company has also ventured into the OTC space, allowing consumers easy access to treatments for common ailments without the need for prescriptions. This segment significantly contributes to the company’s revenue, reflecting its understanding of consumer preferences and market trends.

Healthcare Segment

The company also operates in the development and marketing of healthcare products that focus on wellness and preventive care. This segment aligns with the rising globally recognized trend of preventive healthcare and self-medication.

International Business

In pursuit of global expansion, the company has also made strides into international markets. The company is committed to ensuring that its internationally marketed products maintain the same level of quality that its domestic products are known for.

Research and Development

The company places a strong emphasis on R&D to fuel its innovation pipeline. Continuous investment in R&D allows the company to explore new therapeutic areas and improve existing products based on market needs.

Each business segment operates synergistically, contributing to the company’s overarching goals of providing high-quality healthcare products while ensuring rapid growth and financial stability.

Business Strategy

The company’s business strategy is primarily centered on sustainable growth through innovation, market expansion, and strategic partnerships. The company’s commitment to R&D underpins its aim to develop new products that meet the ever-evolving health needs of society. It has employed an adaptive strategy to harness technology advancements and shifts in market dynamics to maintain its competitive edge.

A significant aspect of the company’s strategy is its focus on compliance and quality assurance. The company is committed to adhering to stringent regulatory standards, thereby ensuring that all products are developed and manufactured with the highest quality benchmarks.

Furthermore, the company emphasizes the importance of market expansion both domestically and internationally. By exploring emerging markets, the company aims to diversify its revenue streams and create a more resilient business model. Strategic partnerships, collaborations, and acquisitions are also pivotal to its growth strategy, allowing the company to leverage complementary strengths and capabilities.

Moreover, the company advocates for corporate social responsibility (CSR) and sustainability in its operations. It aims to minimize the environmental impact associated with pharmaceutical production while operates in community outreach and healthcare initiatives.

Products and Services

The company’s product portfolio is extensive and reflects its commitment to enhancing healthcare access and quality. The company offers a dynamic range of pharmaceutical products that include:

Prescription Medications

This includes a wide array of formulations aimed at treating various health conditions such as cardiovascular diseases, anti-infectives, gastrointestinal disorders, and more. The company focuses on introducing novel formulations that optimize effectiveness, dosage, and patient compliance.

OTC Products

The company’s OTC offerings encompass a broad spectrum of healthcare solutions, from pain relief to allergy medications. The company’s strategy in this segment includes creating products that cater to immediate health needs while fostering brand loyalty through efficacy.

Nutraceuticals and Dietary Supplements

In response to the increasing consumer demand for wellness-oriented products, the company includes nutraceuticals that assist in health maintenance and chronic disease management.

Consumer Health Products

This segment features products aimed at promoting overall health and wellness, targeting consumers looking for preventive care options.

Research Services

Apart from product offerings, the company also supports research initiatives by collaborating with other healthcare entities to develop innovative solutions.

Digital Healthcare Solutions

The company is exploring digital health solutions that facilitate access to medical information and patient management, which is increasingly becoming relevant in a tech-driven healthcare landscape.

Geographical Markets Served

The company has established a strong presence in both domestic and international markets. The company primarily operates within India, addressing the needs of a vast population by providing affordable healthcare solutions.

Seasonality

The company operates in a pharmaceutical landscape that often exhibits certain seasonal trends influenced by health-related factors such as outbreaks of illnesses or seasonal allergies. However, the company ensures that its operations are resilient and structured to meet demands year-round. Continuous monitoring of market conditions and consumer behavior enables the company to adjust production levels and marketing strategies accordingly.

Customers Names, Categories, and Number of Customers Served by the Company

The company serves a diverse customer base, which includes healthcare professionals, pharmacies, hospitals, clinics, and individual consumers. The company’s emphasis on understanding customer needs allows it to tailor its products to meet specific health requirements effectively. The number of customers served extends into millions, reflecting its extensive distribution network and various product categories.

Modes of Sales and Marketing/Distribution Channels

The company employs a multi-channel approach to marketing and distribution, ensuring that its products reach a wide array of consumers. The sales strategy revolves around collaboration with healthcare professionals and pharmacists, fostering strong relationships that facilitate product recommendations. In addition, the company uses digital marketing channels to create awareness and provide information about its products.

The company’s distribution channels span direct sales to healthcare institutions, partnerships with distributors, and e-commerce platforms, thereby enhancing accessibility and ensuring that its products are available to consumers across geographies.

Government Regulations

The company adheres to all applicable laws, including the Drugs and Cosmetics Act and relevant environmental guidelines.

History

Mankind Pharma Limited was founded in 1986. The company was incorporated in 1991.

Mankind Pharma Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical products:** 70% **Consumer goods:** 20% **Veterinary products:** 10% **TOP 3 markets:** **India:** 60% **Southeast Asia:** 20% **Africa:** 10% Mankind Pharma Limited generates the majority of its revenue from the sale of pharmaceutical products, accounting for approx...

At which locations are the company’s products manufactured?

**Production Facilities:** India Mankind Pharma Limited mainly produces its products in India. The company has several production facilities across the country specializing in the manufacturing of pharmaceutical products, health products, and other related items. These production facilities are st...

What strategy does Mankind Pharma pursue for future growth?

**Revenue Growth:** Estimated 10-12% annually (2025-2027) **Focus on Research and Development:** Mankind Pharma is increasing its investment in research and development to bring innovative products to the market. This includes both expanding the existing portfolio and developing new medications. *...

Which raw materials are imported and from which countries?

**Main raw materials:** Active Pharmaceutical Ingredients (APIs), Packaging materials **Countries of origin:** China, Germany, USA, Italy Mankind Pharma Limited mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of their medications. These are primarily...

How strong is the company’s competitive advantage?

**Market share in India:** approximately 4.3% (2023) **Revenue growth:** 16.5% (2023) **EBITDA margin:** 24.1% (2023) Mankind Pharma Limited has established itself as one of the leading players in the Indian pharmaceutical market. With a market share of around 4.3%, the company is among the top...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 23% (2025, estimated) **Insider Buys/Sells:** No significant transactions in the last year (2025) The institutional investor share in Mankind Pharma Limited is estimated to be around 23%. This indicates that a significant portion of the shares are held by instituti...

What percentage market share does Mankind Pharma have?

**Market share of Mankind Pharma Limited:** 5.2% (2025, estimated) **Top competitors and their market shares:** 1. Sun Pharmaceutical Industries Ltd.: 8.9% 2. Cipla Ltd.: 7.5% 3. Dr. Reddy's Laboratories Ltd.: 6.8% 4. Lupin Ltd.: 6.0% 5. Aurobindo Pharma Ltd.: 5.5% 6. Mankind Pharma Limited: 5...

Is Mankind Pharma stock currently a good investment?

**Revenue Growth:** 18% (2024) **EBITDA Margin:** 22% (2024) **R&D Expenses:** 5% of revenue (2024) Mankind Pharma Limited shows a solid revenue growth of 18% in 2024, indicating strong demand for its products and effective market expansion. The EBITDA margin of 22% demonstrates that the co...

Does Mankind Pharma pay a dividend – and how reliable is the payout?

**Dividend Yield:** 1.5% (estimated for 2025) Mankind Pharma Limited has started distributing dividends to its shareholders regularly in recent years. The company's dividend policy shows a tendency towards stability, with payouts remaining constant in recent years. The reliability of dividend...

New support ticket

Explore

Mankind Pharma Stock Value

Mankind Pharma Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Mankind Pharma do?

Mankind Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Mankind Pharma Stock Value

Mankind Pharma Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Mankind Pharma do?

Mankind Pharma Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.